A receptor-antibody hybrid hampering MET-driven metastatic spread

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Background: The receptor encoded by the MET oncogene and its ligand Hepatocyte Growth Factor (HGF) are at the core of the invasive-metastatic behavior. In a number of instances genetic alterations result in ligand-independent onset of malignancy (METaddiction). More frequently, ligand stimulation of wild-type MET contributes to progression toward metastasis (METexpedience). Thus, while MET inhibitors alone are effective in the first case, combination therapy with ligand inhibitors is required in the second condition.Methods: In this paper, we generated hybrid molecules gathering HGF and MET inhibitory properties. This has been achieved by ‘head-to-tail’ or ‘tail-to-head’ fusion of a single chain Fab derived from the DN30 MET antibody with a recombinant ‘ad-hoc’ engineered MET extracellular domain (decoyMET), encompassing the HGF binding site but lacking the DN30 epitope.Results: The hybrid molecules correctly bind MET and HGF, inhibit HGF-induced MET downstream signaling, and quench HGF-driven biological responses, such as growth, motility and invasion, in cancer cells of different origin. Two metastatic models were generated in mice knocked-in by the human HGF gene: (i) orthotopic transplantation of pancreatic cancer cells; (ii) subcutaneous injection of primary cells derived from a cancer of unknown primary. Treatment with hybrid molecules strongly affects time of onset, number, and size of metastatic lesions.Conclusion: These results provide a strategy to treat metastatic dissemination driven by the HGF/MET axis.
Funding Information
  • Associazione Italiana per la Ricerca sul Cancro (21052, 21052)
  • Fondazione Piemontese per la Ricerca sul Cancro (5x1000 2014)
  • Ministero della Salute (Ricerca Corrente 2019)
  • Metis Precision Medicine B-Corp (Resource 2020)

This publication has 51 references indexed in Scilit: